173 related articles for article (PubMed ID: 1394341)
61. Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel.
Ning S; Trisler K; Brown DM; Yu NY; Kanekal S; Lundsten MJ; Knox SJ
Radiother Oncol; 1996 May; 39(2):179-89. PubMed ID: 8735485
[TBL] [Abstract][Full Text] [Related]
62. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
63. Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer.
Berger MA; Masters GR; Singleton J; Scully MS; Grimm LG; Soltis DA; Albone EF
Cancer Biother Radiopharm; 2005 Dec; 20(6):589-602. PubMed ID: 16398611
[TBL] [Abstract][Full Text] [Related]
64. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
[TBL] [Abstract][Full Text] [Related]
65. Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin.
Koppe MJ; Soede AC; Pels W; Oyen WJ; Goldenberg DM; Bleichrodt RP; Boerman OC
Int J Cancer; 2003 Oct; 106(6):965-72. PubMed ID: 12918078
[TBL] [Abstract][Full Text] [Related]
66. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability.
Blumenthal RD; Kashi R; Sharkey RM; Goldenberg DM
Int J Cancer; 1995 May; 61(4):557-66. PubMed ID: 7759161
[TBL] [Abstract][Full Text] [Related]
67. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
[TBL] [Abstract][Full Text] [Related]
68. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.
Shih LB; Xuan H; Aninipot R; Stein R; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5857s-5863s. PubMed ID: 7493360
[TBL] [Abstract][Full Text] [Related]
69. Direct measurement of intratumor dose-rate distributions in experimental xenografts treated with 90Y-labeled radioimmunotherapy.
Mayer R; Dillehay LE; Shao Y; Zhang YG; Song S; Bartholomew RM; Mackenson DG; Williams JR
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):147-57. PubMed ID: 7721611
[TBL] [Abstract][Full Text] [Related]
70. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
[TBL] [Abstract][Full Text] [Related]
71. Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy.
Kim EJ; Kim BS; Choi DB; Chi SG; Choi TH
Oncol Rep; 2016 Jun; 35(6):3159-68. PubMed ID: 27035553
[TBL] [Abstract][Full Text] [Related]
72. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
73. Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts.
Steffens MG; Kranenborg MH; Boerman OC; Zegwaart-Hagemeier NE; Debruyne FM; Corstens FH; Oosterwijk E
Cancer Biother Radiopharm; 1998 Apr; 13(2):133-9. PubMed ID: 10850349
[TBL] [Abstract][Full Text] [Related]
74. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
Ning S; Trisler K; Wessels BW; Knox SJ
Cancer; 1997 Dec; 80(12 Suppl):2519-28. PubMed ID: 9406705
[TBL] [Abstract][Full Text] [Related]
75. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
Stein R; Goldenberg DM; Thorpe SR; Mattes MJ
J Nucl Med; 1997 Mar; 38(3):391-5. PubMed ID: 9074526
[TBL] [Abstract][Full Text] [Related]
76. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
77. [186Re]-labeled mouse and chimeric monoclonal antibody 323/A3: a comparison of the efficacy in experimental human ovarian cancer.
Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
Nucl Med Biol; 1998 Jan; 25(1):37-45. PubMed ID: 9466360
[TBL] [Abstract][Full Text] [Related]
78. Autoradiography-based, three-dimensional calculation of dose rate for murine, human-tumor xenografts.
Koral KF; Kwok CS; Yang FE; Brown RS; Sisson JC; Wahl RL
Nucl Med Biol; 1993 Nov; 20(8):901-9. PubMed ID: 8298569
[TBL] [Abstract][Full Text] [Related]
79. Improving radioimmonotargeting of tumors. Variation in the amount of L6 MAb administered, combined with an immunoadsorption system (ECIA).
Garkavij M; Tennvall J; Strand SE; Norrgren K; Nilsson R; Lindgren L; Sjögren HO
Acta Oncol; 1993; 32(7-8):853-9. PubMed ID: 8305236
[TBL] [Abstract][Full Text] [Related]
80. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
